Страна: Ирландия
Язык: английский
Источник: HPRA (Health Products Regulatory Authority)
Cefuroxime
Sandoz Pharmaceuticals d.d.
J01DC; J01DC02
Cefuroxime
Film-coated tablet
Second-generation cephalosporins; cefuroxime
Marketed
1989-08-04
PACKAGE LEAFLET: INFORMATION FOR THE USER ZINNAT 125 MG FILM-COATED TABLETS ZINNAT 250 MG FILM-COATED TABLETS ZINNAT 500 MG FILM-COATED TABLETS cefuroxime READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : 1. What Zinnat is and what it is used for 2. What you need to know before you take Zinnat 3. How to take Zinnat 4. Possible side effects 5. How to store Zinnat 6. Contents of the pack and other information 1. WHAT ZINNAT IS AND WHAT IT IS USED FOR Zinnat is an antibiotic used in adults and children. It works by killing bacteria that cause infections. It belongs to a group of medicines called _cephalosporins_ . Zinnat is used to treat infections of: the throat sinus middle ear the lungs or chest the urinary tract the skin and soft tissues. Zinnat can also be used: to treat Lyme disease (an infection spread by parasites called ticks). Your doctor may test the type of bacteria causing your infection and monitor whether the bacteria are sensitive to Zinnat during your treatment. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZINNAT DO NOT TAKE ZINNAT: IF YOU ARE ALLERGIC to cefuroxime axetil or ANY CEPHALOSPORIN ANTIBIOTICS or any of the other ingredients of Zinnat (listed in section 6). if you have ever had a severe allergic (hypersensitive) reaction to any other type of beta-lactam antibiotic (penicillins, monobactams and carbapenems). if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after treatment with cefur Прочитать полный документ
Health Products Regulatory Authority 04 January 2024 CRN00F19Z Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zinnat 125 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 125 mg cefuroxime (as cefuroxime axetil). Excipients with known effect: Each tablet contains 0.00152 mg sodium benzoate (E211) Each tablet contains 0.06 mg methyl parahydroxybenzoate (E218) and 0.04 mg propyl parahydroxybenzoate (E216) For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet (tablet) 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months (see sections 4.4 and 5.1). Acute streptococcal tonsillitis and pharyngitis. Acute bacterial sinusitis. Acute otitis media. Acute exacerbations of chronic obstructive pulmonary disease. Cystitis. Pyelonephritis. Uncomplicated skin and soft tissue infections. Treatment of early Lyme disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The usual course of therapy is seven days (may range from five to ten days). The dose of cefuroxime that is selected to treat an individual infection should take into account: The expected pathogens and their likely susceptibility to cefuroxime axetil The severity and the site of the infection The age, weight and renal function of the patient; as shown below.The duration of therapy should be determined by the type of infection and the response of the patient and should generally not be longer than recommended. _Table 1. Adults and children (> 40 kg)_ INDICATION DOSAGE Acute tonsillitis and pharyngitis, acute bacterial sinusitis 250 mg twice daily Health Products Regulatory Authority 04 January 2024 CRN00F19Z Page 2 of 11 Acute otitis media 500 mg twice daily Acute exacerbations of chronic obstructive pulmon Прочитать полный документ